Forte Biosciences, Inc. (FBRX)

NCM – Цена в реальном времени. Валюта: USD

21.03

+2.32 (12.40%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

21.03

0.00 (0.00%)

После закрытия: Jun 26, 2026, 4:43 PM EDT

11.05.2026

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its c.

11.05.2026

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. “FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102's potential to address the high unmet need in celiac disease. The clinical development for FB102 continue.

10.04.2026

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102, its multi-indication anti-CD122 antibody, on multiple fronts. FB102 demonstrated statistically significant Phase 1b efficacy in Celiac disease, positioning FBRX as a potential frontrunner for first drug approval in this indication. Upcoming Phase 1b data in vitiligo and alopecia areata, both large and competitive markets, represent major catalysts for FBRX in 2024.

09.04.2026

Forte Biosciences Announces Pricing of $150 Million Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its common stock at the public offering price, less the underwriting discounts and comm.

08.04.2026

Forte Biosciences Announces Proposed Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock. All of the shares of common stock are being offered by Forte. The proposed offering is su.

31.03.2026

Forte Biosciences, Inc. Announces 2025 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year 2025 financial results and provided a business update. “The clinical development for FB102 continues to progress well with important readouts in 2026,” said Forte Biosciences CEO Paul Wagner, PhD. “The topline results from our phase 2 celiac disease study is expected in 2026. Based on.

17.03.2026

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Boa.

Видео

No Data

There is no data to display

Пресс-релизы

11.05.2026

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

11.05.2026

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. “FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102's potential to address the high unmet need in celiac disease. The clinical development for FB102 continue.

09.04.2026

Forte Biosciences Announces Pricing of $150 Million Public Offering

08.04.2026

Forte Biosciences Announces Proposed Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock. All of the shares of common stock are being offered by Forte. The proposed offering is su.

Forte Biosciences, Inc. (FBRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Forte Biosciences, Inc. (FBRX)

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences, Inc. Announces 2025 Results and Provides Update

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Видео

No Data

Пресс-релизы

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences, Inc. Announces 2025 Results and Provides Update

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Видео

No Data

Пресс-релизы

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Search stocks

Forte Biosciences, Inc. (FBRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Forte Biosciences, Inc. (FBRX)

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences, Inc. Announces 2025 Results and Provides Update

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Видео

No Data

Пресс-релизы

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences, Inc. Announces 2025 Results and Provides Update

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Видео

No Data

Пресс-релизы

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences Announces Proposed Public Offering